Randomized phase II trial of adjuvant chemotherapy (CBDCA+GEM vs TS1+DTX) for completely resected non-small cell lung cancer

Randomized phase II trial of adjuvant chemotherapy (CBDCA+GEM vs TS1+DTX) for completely resected non-small cell lung cancer - CBDCA+GEM vs TS1+DTX phase II trial for completely resected lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000781

Enrollment

120

Registered

2007-08-01

Start date

2007-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

adjuvant chemotherapy with CBDCA+GEM adjuvant chemotherapy with TS1+DTX

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: non-small cell lung cancer lobectomy or more with ND2 lymphnode dissection complete resection pathological stage IB, II, IIIA ECOG performance status 0, 1

Exclusion criteria

Exclusion criteria: symptomatic interstitial pneumonia multiple lung cancer or other-type cancer within 5 years severe organ failure past history of radiotherapy or chemotherapy pregnant or expecting mother

Design outcomes

Primary

Measure	Time frame
2-year relapse free survival	—

Secondary

Measure	Time frame
toxicity	—

Countries

Japan

Contacts

Public ContactChiaki Endo

Japanese Northern East Area Thoracic Surgery Study Group Central study center

endo@idac.tohoku.ac.jp022-717-8526

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026